NCT07384234

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Randomized, Two-Cohort Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.

Conditions

• Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	SHR-1701	SHR-1701, 1800mg, Q3w
DRUG	Capecitabine	Capecitabine, Q3W
DRUG	S-1	S-1, Q3W
DRUG	Paclitaxel	Paclitaxel,Q3W
DRUG	Oxaliplatin	Oxaliplatin, Q3W

Timeline

• Start date: 2026-01-31
• Primary completion: 2028-12-30
• Completion: 2030-12-30
• First posted: 2026-02-03
• Last updated: 2026-02-03

Locations

2 sites across 1 country: China